Profusa, Inc. (NASDAQ:PFSA) Short Interest Update

Profusa, Inc. (NASDAQ:PFSA) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totaling 665,135 shares, an increase of 1,666.7% from the April 15th total of 37,649 shares. Currently, 17.0% of the company’s stock are short sold. Based on an average daily volume of 2,488,159 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PFSA. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Profusa in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Profusa has a consensus rating of “Sell”.

Profusa Stock Down 3.5%

Shares of NASDAQ:PFSA traded down $0.02 on Wednesday, reaching $0.43. The company’s stock had a trading volume of 182,711 shares, compared to its average volume of 3,551,189. The business has a 50-day moving average price of $0.73. Profusa has a 52-week low of $0.41 and a 52-week high of $180.00. The company has a market cap of $1.90 million, a PE ratio of 0.00 and a beta of 0.47.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.